CD274 and familial pancreatic carcinoma: A Phase I clinical trial (NCT03481920) is currently underway to evaluate the pharmacodynamics and efficacy of PEGPH20 plus avelumab (anti-PD-L1 mAb) in chemotherapy-resistant pancreatic cancer patients [173].